非ホジキンリンパ腫（B細胞リンパ腫）：市場機会及び予測（～2018）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 13
1.2 List of Figures 15
2 Introduction 17
2.1 Catalyst 17
2.2 Related Reports 17
2.3 Upcoming Related Reports 17
3 Disease Overview 18
3.1 Etiology and Pathophysiology 18
3.1.1 Pathophysiology of Indolent and Aggressive B-Cell NHL 19
3.2 Symptoms 23
4 Disease Management 24
4.1 Diagnosis 24
4.1.1 Diagnostic Classification 25
4.2 Treatment Overview 27
5 Epidemiology 33
5.1 Disease Background 33
5.2 Risk Factors and Comorbidities 33
5.3 Global Trends 35
5.3.1 US 36
5.3.2 US 36
5.3.3 5EU 37
5.4 Forecast Methodology 40
5.4.1 Sources Used 42
5.4.2 Forecast Assumptions and Methods 44
5.4.3 Age-Standardized Incidence Rates 48
5.5 Epidemiological Forecast for B-Cell NHL (2013-2023) 48
5.5.1 Follicular Lymphoma 48
5.5.2 Marginal Zone Lymphoma 54
5.5.3 DLBCL 59
5.5.4 Mantle Cell Lymphoma 64
5.6 Discussion 71
5.6.1 Epidemiological Forecast Insight 71
5.6.2 Limitations of the Analysis 72
5.6.3 Strengths of the Analysis 73
6 Current Treatment Options 74
6.1 Overview 74
6.2 Product Profiles – Major Brands, Follicular Lymphoma 76
6.2.1 Imbruvica (ibrutinib) 76
6.2.2 Revlimid (lenalidomide) 80
6.2.3 Rituxan/MabThera (rituximab) 85
6.2.4 Treanda (bendamustine) 91
6.2.5 Velcade (bortezomib) 93
6.2.6 Zevalin (ibritumomab tiuxetan) 96
6.2.7 Zydelig (idelalisib, GS-1101, CAL-101) 100
7 Unmet Needs Assessment and Opportunity Analysis 104
7.1 Overview 104
7.2 Unmet Needs Analysis 104
7.2.1 Unmet Need: Safe and Tolerable Front-Line Agents for Indolent NHL Patients that Prolong OS and Delay Relapse 104
7.2.2 Unmet Need: Prolonged Survival Rates for Mantle Cell Patients 105
7.2.3 Unmet Need: Improved Cure Rate for DLBCL Patients after Front-Line Therapy 105
7.2.4 Unmet Need: Predictive and Prognostic Molecular Biomarkers 106
7.3 Opportunity Analysis 107
7.3.1 Opportunity: More Cost-Effective Therapies 107
7.3.2 Opportunity: Better Consolidation/Maintenance Therapies for Follicular Patients 107
7.3.3 Novel Agents for Front-Line DLBCL and Mantle Cell Lymphoma Therapy 108
8 R&D Strategies 109
8.1 Overview 109
8.1.1 Targeting Multiple NHL Subtypes and Lines of Therapy to Capture Greatest Patient Share 110
8.1.2 Inhibiting New Targets in Relapsed/Refractory NHL Patients 111
8.1.3 Developing Novel Drugs in Combination with Rituxan/MabThera to Replace Chemoimmunotherapy Regimens 112
8.1.4 Franchise Management through Developing Novel Second-Generation Therapies to Replace Established Standards of Care at the End of Their Patent Life 112
8.1.5 Small Biotechs Collaborating on Investigator-Sponsored Early-Stage Trials to De-Risk Later-Stage Studies 113
8.1.6 Introducing New Routes of Drug Delivery to Improve Patient Convenience 114
8.2 Clinical Trial Design 115
8.2.1 Indolent B-Cell NHL 115
8.2.2 Aggressive B-Cell NHL 117
8.2.3 Clinical Endpoints 118
8.2.4 Comparator Arms 119
9 Pipeline Assessment 121
9.1 Overview 121
9.2 Promising Drugs in Clinical Development 121
9.2.1 Arzerra (ofatumumab) 122
9.2.2 Gazyva (obinutuzumab) 125
9.3 Innovative Early-Stage Approaches 130
9.3.1 Adcetris (brentuximab vedotin) 132
9.3.2 Alisertib (MLN8237) 132
9.3.3 Blinatumomab (AMG-101) 133
9.3.4 Copanlisib (BAY 80-6946) 133
9.3.5 Y-90 Epratuzumab 134
9.3.6 Chimeric Antigen Receptor T-Cell Therapies 135
10 Pipeline Valuation Analysis 136
10.1 Clinical Benchmark of Key Pipeline Drugs 136
10.2 Commercial Benchmark of Key Pipeline Drugs 139
10.3 Competitive Assessment 140
10.4 Top Line Five Year Forecast 142
10.4.1 US 144
10.4.2 5EU 145
11 Appendix 146
11.1 Bibliography 146
11.2 Abbreviations 162
11.3 Methodology 168
11.4 Forecasting Methodology 168
11.4.1 Diagnosed NHL patients 168
11.4.2 Percent Drug-Treated Patients 168
11.4.3 Drugs Included in Each Therapeutic Class 169
11.4.4 Launch and Patent Expiry Dates 169
11.4.5 General Pricing Assumptions 170
11.4.6 Individual Drug Assumptions 170
11.4.7 Generic Erosion 173
11.4.8 Pricing of Pipeline agents 173
11.5 Physicians and Specialists Included in This Study 174
11.6 Survey of Prescribing Physicians 174
11.7 About the Authors 175
11.7.1 Authors 175
11.7.2 Epidemiologist 176
11.7.3 Global Head of Healthcare 176
11.8 About GlobalData 177
11.9 Disclaimer 177